Matthew J A Wood

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Therapeutic gene silencing in the nervous system
    Matthew J A Wood
    Department of Human Anatomy and Genetics, Oxford University, Oxford, UK
    Hum Mol Genet 12:R279-84. 2003
  2. ncbi request reprint Ribozymes and siRNA for the treatment of diseases of the nervous system
    Matthew J Wood
    Department of Human Anatomy and Genetics, Oxford University, South Parks Road, Oxford, OX1 3QX, UK
    Curr Opin Mol Ther 5:383-8. 2003
  3. doi request reprint Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
    Lydia Alvarez-Erviti
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Nat Biotechnol 29:341-5. 2011
  4. pmc Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse
    HaiFang Yin
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Mol Ther 18:819-27. 2010
  5. doi request reprint Exosomes for targeted siRNA delivery across biological barriers
    Samir El Andaloussi
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, United Kingdom
    Adv Drug Deliv Rev 65:391-7. 2013
  6. pmc Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224
    Christopher R Sibley
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Nucleic Acids Res 40:9863-75. 2012
  7. pmc Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation
    Anna M L Coenen-Stass
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Hum Mol Genet . 2016
  8. pmc Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration
    Thomas C Roberts
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK, Sanford Burnham Prebys Medical Discovery Institute, Development, Aging and Regeneration Program, 10901 N Torrey Pines Road, La Jolla, CA 92037, USA
    Hum Mol Genet 24:6756-68. 2015
  9. pmc Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy
    Corinne A Betts
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, UK, OX1 3QX
    Sci Rep 5:11632. 2015
  10. pmc Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics
    Anna M L Coenen-Stass
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK
    Sci Rep 5:17014. 2015

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Therapeutic gene silencing in the nervous system
    Matthew J A Wood
    Department of Human Anatomy and Genetics, Oxford University, Oxford, UK
    Hum Mol Genet 12:R279-84. 2003
    ....
  2. ncbi request reprint Ribozymes and siRNA for the treatment of diseases of the nervous system
    Matthew J Wood
    Department of Human Anatomy and Genetics, Oxford University, South Parks Road, Oxford, OX1 3QX, UK
    Curr Opin Mol Ther 5:383-8. 2003
    ..This review will assess the potential of these RNA-based therapeutic strategies and the challenges ahead in their application to the treatment of neurological disease...
  3. doi request reprint Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
    Lydia Alvarez-Erviti
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Nat Biotechnol 29:341-5. 2011
    ..The therapeutic potential of exosome-mediated siRNA delivery was demonstrated by the strong mRNA (60%) and protein (62%) knockdown of BACE1, a therapeutic target in Alzheimer's disease, in wild-type mice...
  4. pmc Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse
    HaiFang Yin
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Mol Ther 18:819-27. 2010
    ..PNA AOs therefore provide an attractive candidate AO chemistry for DMD exon skipping therapy...
  5. doi request reprint Exosomes for targeted siRNA delivery across biological barriers
    Samir El Andaloussi
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, United Kingdom
    Adv Drug Deliv Rev 65:391-7. 2013
    ....
  6. pmc Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224
    Christopher R Sibley
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Nucleic Acids Res 40:9863-75. 2012
    ..Thus, the unique characteristics of artificial mirtrons make this an attractive approach for future RNAi applications...
  7. pmc Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation
    Anna M L Coenen-Stass
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Hum Mol Genet . 2016
    ..These findings have implications for the use of ex-myomiRs as biomarkers for DMD disease progression and monitoring response to therapy...
  8. pmc Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration
    Thomas C Roberts
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK, Sanford Burnham Prebys Medical Discovery Institute, Development, Aging and Regeneration Program, 10901 N Torrey Pines Road, La Jolla, CA 92037, USA
    Hum Mol Genet 24:6756-68. 2015
    ..This study provides fundamental new insights into gene expression and regulation in dystrophic muscle. ..
  9. pmc Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy
    Corinne A Betts
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, UK, OX1 3QX
    Sci Rep 5:11632. 2015
    ..This supports the requirement of a body-wide therapy to treat DMD. ..
  10. pmc Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics
    Anna M L Coenen-Stass
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK
    Sci Rep 5:17014. 2015
    ..This study has identified multiple novel, therapy-responsive protein biomarkers in the serum of the mdx mouse with potential utility in DMD patients. ..
  11. pmc Cells release subpopulations of exosomes with distinct molecular and biological properties
    Eduard Willms
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, United Kingdom
    Sci Rep 6:22519. 2016
    ..Further dissection of exosome heterogeneity will advance our understanding of exosomal biology in health and disease and accelerate the development of exosome-based diagnostics and therapeutics. ..
  12. pmc Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice
    Corinne A Betts
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, UK, OX1 3QX
    Sci Rep 5:8986. 2015
    ..This work demonstrates that high levels of cardiac dystrophin restored by Pip peptide-AOs prevents further deterioration of cardiomyopathy and pathology following exercise in dystrophic DMD mice. ..
  13. doi request reprint Exosome-mediated delivery of siRNA in vitro and in vivo
    Samir El-Andaloussi
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Nat Protoc 7:2112-26. 2012
    ..Examples of anticipated results in which exosome-mediated siRNA delivery is evaluated by functional assays and imaging are also provided. The entire protocol takes ~3 weeks...
  14. pmc The biogenesis and characterization of mammalian microRNAs of mirtron origin
    Christopher R Sibley
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK
    Nucleic Acids Res 40:438-48. 2012
    ..This work confirms the mirtron origins of three mammalian miRNAs and suggests that they are a functional class of splicing-dependent miRNAs which are physiologically active...
  15. pmc Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover
    Thomas C Roberts
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK, Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA, Dubowitz Neuromuscular Centre, UCL Institute of Child Health, 30 Guildford Street, London, WC1N 1EH, UK and Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Level 3, Women s Centre, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Nucleic Acids Res 41:9500-13. 2013
    ..In conclusion, extracellular miRNAs are dynamic indices of pathophysiological processes in skeletal muscle. ..
  16. ncbi request reprint Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy
    Yi Lee
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Hum Mol Genet 21:R125-34. 2012
    ..Thus, extracellular vesicles are emerging as potent genetic information transfer agents underpinning a range of biological processes and with therapeutic potential...
  17. ncbi request reprint Use of cell-penetrating-peptides in oligonucleotide splice switching therapy
    Samir A El Andaloussi
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, United Kingdom
    Curr Gene Ther 12:161-78. 2012
    ..This review provides insight into the application of CPPs and ONs in gene regulation with particular focus on CPP-assisted delivery of therapeutic SSOs...
  18. doi request reprint RNA therapy for polyglutamine neurodegenerative diseases
    Lauren M Watson
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Expert Rev Mol Med 14:e3. 2012
    ..However, numerous technical obstacles associated with design, discrimination and delivery must be overcome before RNA therapy can be effectively applied in the clinical setting...
  19. doi request reprint RNA-targeted splice-correction therapy for neuromuscular disease
    Matthew J A Wood
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Brain 133:957-72. 2010
    ....
  20. pmc Transfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases
    Miguel A Varela
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Eur J Hum Genet 24:271-6. 2016
    ..We therefore provide fundamental knowledge on strategies for optimising patient coverage of therapeutics for microsatellite expansion disorders by linking analysis of population genetic variation to the selection of molecular targets. ..
  21. pmc Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells
    Taavi Lehto
    UMR 5235 CNRS, Universite Montpellier 2, Place Eugene Bataillon, Montpellier 34095, France, Centre de Recherche de Biochimie Macromoleculaire, UMR 5237 CNRS, 1919 Route de Mende, 34293 Montpellier, France, Universitat Potsdam, Institut für Biochemie und Biologie, Maulbeerallee 2, 14469 Potsdam, Germany, Medical Research Council, Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK and Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK
    Nucleic Acids Res 42:3207-17. 2014
    ..Overall, Pip6a-PMO appears as the most efficient conjugate to date (low nanomolar EC50), even if limitations remain from endosomal escape. ..
  22. ncbi request reprint Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy
    Corinne A Betts
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK
    Curr Pharm Des 19:2948-62. 2013
    ..These cell penetrating peptides, combined with an optimised dose and dosing regimen, as well as thorough toxicity profile have the potential to be developed into a promising treatment which may be progressed to clinical trial...
  23. doi request reprint Extracellular vesicles: biology and emerging therapeutic opportunities
    Samir El Andaloussi
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Nat Rev Drug Discov 12:347-57. 2013
    ..Here, we review recent progress in understanding extracellular vesicle biology and the role of extracellular vesicles in disease, discuss emerging therapeutic opportunities and consider the associated challenges...
  24. doi request reprint Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers
    Samira Lakhal
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Bioessays 33:737-41. 2011
    ....
  25. doi request reprint Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge
    Matthew J A Wood
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3QX, UK
    Sci Transl Med 2:25ps15. 2010
    ..This is therefore a highly complex drug development challenge...
  26. doi request reprint D-amino acid oxidase knockdown in the mouse cerebellum reduces NR2A mRNA
    Philip W J Burnet
    Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK
    Mol Cell Neurosci 46:167-75. 2011
    ..They also provide a tool to investigate DAO, an enzyme currently of considerable interest in the pathophysiology and therapy of schizophrenia...
  27. ncbi request reprint Neuropathological consequences of delivering an adenoviral vector in the rat brain
    M Mary McMenamin
    Department of Human Anatomy and Genetics, University of Oxford, Oxford OX1 3QX, UK
    J Gene Med 6:740-50. 2004
    ..To investigate optimisation of this we injected different doses of vector and have documented the neuropathological side effects...
  28. doi request reprint RNA splicing: disease and therapy
    Andrew G L Douglas
    Department of Physiology, Anatomy and Genetics, University of Oxford, UK
    Brief Funct Genomics 10:151-64. 2011
    ..Antisense oligonucleotide therapies show particular promise in this area and, if coupled with improved delivery strategies, could open the door to a multitude of novel personalized therapies...
  29. ncbi request reprint Preparation and Isolation of siRNA-Loaded Extracellular Vesicles
    Pieter Vader
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Methods Mol Biol 1545:197-204. 2017
    ..In this chapter we describe a method for preparing siRNA-loaded EVs, including a robust, scalable method to isolate them from cell culture supernatants...
  30. pmc Detection and quantification of extracellular microRNAs in murine biofluids
    Thomas C Roberts
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, OX1 3QX Oxford, UK
    Biol Proced Online 16:5. 2014
    ..Protocols for the detection and quantification of miRNAs in biofluids are therefore of high interest...
  31. doi request reprint Mirtrons, an emerging class of atypical miRNA
    Helen J Curtis
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Wiley Interdiscip Rev RNA 3:617-32. 2012
    ..In addition, through exploitation of the potent and sequence-specific silencing capabilities of RNAi, synthetic mirtrons may have potential for overcoming certain therapeutic challenges...
  32. doi request reprint The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy
    Christopher R Sibley
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK
    J Mol Med (Berl) 89:1065-77. 2011
    ..Finally, we highlight the many ways in which the miRNA pathway may be targeted for therapeutic benefit...
  33. doi request reprint Genetic therapies for RNA mis-splicing diseases
    Suzan M Hammond
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, UK, OX1 3QX
    Trends Genet 27:196-205. 2011
    ..The success of clinical trials for modifying splicing to treat Duchenne muscular dystrophy opens the door for the use of splicing modification for most of the mis-splicing diseases...
  34. doi request reprint Identification of a novel muscle targeting peptide in mdx mice
    Yiqi Seow
    Department of Physiology, Anatomy and Genetics, Le Gros Clark Building, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Peptides 31:1873-7. 2010
    ..This work has many potential applications for oligonucleotide or drug delivery to muscle for myopathies...
  35. pmc Extracellular vesicles: emerging targets for cancer therapy
    Pieter Vader
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX1 3QX, UK
    Trends Mol Med 20:385-93. 2014
    ..Here, we summarise the current knowledge on the contributions of EVs to cancer pathogenesis and discuss novel therapeutic strategies to target EVs to prevent tumour growth and spread. ..
  36. doi request reprint Therapeutic targeting of non-coding RNAs
    Thomas C Roberts
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Essays Biochem 54:127-45. 2013
    ..The ability to modulate gene expression at the epigenetic level presents exciting new opportunities for the treatment of human disease. ..
  37. pmc Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy
    Yoshitsugu Aoki
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Biomed Res Int 2013:402369. 2013
    ..Here we discuss and review the latest preclinical work in this area as well as a variety of accompanying issues, including efficacy and potential toxicity of antisense oligonucleotides, prior to human clinical trials. ..
  38. pmc Epigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy
    Miguel A Varela
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK
    Neurotherapeutics 10:621-31. 2013
    ..Here we describe the interactions between epigenetic and ncRNA regulatory systems and discuss therapeutic potential, with an emphasis on tumors, cognitive disorders and neurodegenerative diseases. ..
  39. doi request reprint Optimizing tissue-specific antisense oligonucleotide-peptide conjugates
    Corinne A Betts
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Methods Mol Biol 867:415-35. 2012
    ..Physiological and functional correction of dystrophin protein may be confirmed by a number of techniques as described and allows for the fast-tracking of candidate peptides to drug trial for DMD...
  40. doi request reprint A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice
    HaiFang Yin
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Hum Mol Genet 18:4405-14. 2009
    ..Our data demonstrate proof-of-concept for this chimeric peptide approach in DMD splice correction therapy and is likely to have broad application...
  41. doi request reprint Therapeutic gene silencing strategies for polyglutamine disorders
    Janine Scholefield
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX13QX, UK
    Trends Genet 26:29-38. 2010
    ..Insights from polyglutamine gene function studies and the further development of allele-specific and other gene silencing methodologies will be important to determine the optimal therapeutic strategy for each polyglutamine disorder...
  42. doi request reprint Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function
    HaiFang Yin
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Hum Mol Genet 17:3909-18. 2008
    ..Peptide-conjugated AOs therefore have significant potential for systemic correction of the DMD phenotype...
  43. ncbi request reprint Readministration of adenoviral gene delivery to dopamine neurons
    Sarah C Gonzalez
    Department of Physiology Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, UK
    Neuroreport 18:1609-14. 2007
    ..Our findings indicate that transgene expression declined in dopamine neurons despite the persistence of virus, and the capacity to readminister vector to these neurons was limited...
  44. doi request reprint Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy
    Tirsa L E van Westering
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, OX1 3QX, UK
    Molecules 20:8823-55. 2015
    ..It briefly discusses the current treatment options and then elaborates on the preclinical therapeutic approaches currently under development to restore dystrophin thereby improving pathology, with a focus on the heart. ..
  45. pmc Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts
    Janine Scholefield
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Eur J Hum Genet 22:1369-75. 2014
    ....
  46. pmc Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy
    Michalis Papadakis
    Laboratory of Cerebral Ischemia, Acute Stroke Programme, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
    Nat Med 19:351-7. 2013
    ..Overexpression of hamartin increased resistance to OGD by inducing productive autophagy through an mTORC1-dependent mechanism...
  47. doi request reprint Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line
    Lydia Alvarez-Erviti
    Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford OX1 3QX, UK
    Neurosci Res 69:337-42. 2011
    ..These results support the hypothesis that WT and A53T alpha-synuclein has an important role in the initiation and maintenance of inflammation in PD, through the activation of a pro-inflammatory response in microglial cells...
  48. pmc Novel RNA-based strategies for therapeutic gene silencing
    Christopher R Sibley
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Mol Ther 18:466-76. 2010
    ..This review discusses RNA-mediated silencing in light of this recent research, and highlights the benefits and limitations conferred by these novel gene-silencing strategies...
  49. doi request reprint Th1 cytokines are upregulated by adenoviral vectors in the brains of primed mice
    Marco B Lee
    University of Oxford, Department of Physiology, Anatomy and Genetics, Oxford, UK
    Neuroreport 19:1187-92. 2008
    ..This knowledge of the molecular regulation of the immune response provides insight into targets, which could be manipulated to reduce inflammation in immunologically primed animals...
  50. ncbi request reprint Delivering RNA interference to the mammalian brain
    Timothy M Fountaine
    The Wellcome Trust Centre for Human Genetics, University of Oxford, UK
    Curr Gene Ther 5:399-410. 2005
    ..Finally, potential problems that must be considered before applying this technology to the human brain are outlined...